SCHEMBL6715754

SCHEMBL6715754

Cc1cccc(NC(=O)C(c2ccccc2)N(S)C(=O)Nc2ccccc2C(F)(F)F)c1C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 5/20 0.42
ALOX12 P18054 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
TSHR P16473 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.40
NPC1 O15118 1/20 0.40
THRB P10828 1/20 0.40
RAB9A P51151 1/20 0.40
NOX1 Q9Y5S8 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715503 0.93 POLB (0.44) MAPTPOLBMAPK1ALDH1A1ALOX12
SCHEMBL6716817 0.93 POLB (0.42) MAPTPOLBMAPK1ALDH1A1ALOX12
SCHEMBL6714006 0.85 ALDH1A1 (0.45) POLBMAPK1ALDH1A1MEN1KMT2A
SCHEMBL6717563 0.85 POLB (0.43) MAPTPOLBMAPK1ALDH1A1MEN1
SCHEMBL6717048 0.85 GRIK1 (0.48) MAPTPOLBMAPK1ALDH1A1ALOX12
SCHEMBL6714154 0.84 CASR (0.47) POLBMAPK1ALDH1A1MEN1KMT2A
SCHEMBL6717397 0.84 LMNA (0.53) MAPTPOLBMAPK1ALDH1A1ALOX12
SCHEMBL6714030 0.83 ALDH1A1 (0.44) MAPTPOLBMAPK1ALDH1A1MEN1
SCHEMBL6717097 0.83 GAA (0.46) POLBMAPK1ALDH1A1KMT2AKDM4E
SCHEMBL6716927 0.83 L3MBTL1 (0.43) POLBALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MAPT 427/4885POLB 4182/4885MAPK1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.